Last reviewed · How we verify
rhTPO
At a glance
| Generic name | rhTPO |
|---|---|
| Also known as | Decitabine, Aclarubicin, G-CSF, Cytarabine, BMS-IMRT |
| Sponsor | Yin Jie |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- rhTPO Dose Escalation vs Eltrombopag Switch in ITP (NA)
- Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA (PHASE2)
- A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. (PHASE2)
- TPO Combined With TPORA for Solid Tumors Effectiveness of cTit Above Degree II
- The Use of Eltrombopag Post HSCT in BMFD (PHASE2, PHASE3)
- Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma (NA)
- Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP (PHASE4)
- A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhTPO CI brief — competitive landscape report
- rhTPO updates RSS · CI watch RSS
- Yin Jie portfolio CI